<DOC>
	<DOC>NCT03043248</DOC>
	<brief_summary>This study comprises 2 cohorts, and in each cohort, the study will be conducted as an open-label add-on study. The purpose of the study is to investigate the pharmacokinetics of each substrate in concomitant administration of a single dose of the P-glycoprotein substrate digoxin (Cohort A) or the CYP3A4 substrate midazolam (Cohort B) during repeated administration of TRK-700 in healthy adult males.</brief_summary>
	<brief_title>TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Japanese healthy adult males. Subjects with a BMI of at least 18.0 and less than 30.0 at the screening examination and the examination at admission. Subjects with significant concomitant or historical disease of the metabolism, liver, kidneys, blood, lungs, heart, digestive organs, urinary organs, or nerves, or psychiatric diseases, accompanied by clinical symptoms or with other clinically significant disease, who are unsuitable for participation in this study, in the opinion of the investigators. Subjects who are found by the investigators to have significant clinical abnormality at the screening examination, the examination at admission, or the examination at the day of first administration of Digoxin or Midazolam.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TRK-700</keyword>
	<keyword>PK</keyword>
	<keyword>Digoxin</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Drug-Drug interaction</keyword>
	<keyword>P-glycoprotein</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>MDR1</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>multidrug resistance 1</keyword>
</DOC>